Novo Nordisk announced a $11 billion acquisition of three production factories to meet the growing demand for weight loss drugs. On January 31st, Novo Nordisk released its 2023 results, with a total annual revenue of approximately $33.771 billion, a year-on-year increase of 31%. As a star product of Novo Nordisk, Smegglutide earned approximately $21.201 billion in sales in 2023.
The popularity of weight loss pills has driven Novo Nordisk to expand production capacity and also contributed to its strong performance growth. On the one hand, weight loss pills have validated the logic of pharmaceutical companies for large single products, and on the other hand, the concept of weight loss is also expected to drive domestic related enterprises to usher in a new round of market attention.